A new treatment option for patients who have androgen-resistant prostate cancer (ARPC) is now available at Maimonides Cancer Center. Maimonides has been selected as a participant in an international trial of abiraterone acetate, a brand new hormonal treatment shown in a recent phase III trial to extend survival for patients with chemotherapy-resistant disease. At present, abiraterone acetate is neither FDA-approved, nor commercially available. Johnson & Johnson will be providing abiraterone acetate free of charge to all study participants.  Eligible patients must have received 1 or 2 chemotherapy regimens (1 of which contained a taxane, such as docetaxel) and have progressive disease.